#HoraEst @ammaraj.bsky.social 🇺🇸 #PhD ceremony today in A’dam 🇳🇱
⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a…

#PhD team: Chris Wolfgang, Jin He, Lois Daamen

@amsterdamumc.bsky.social @pancpals.bsky.social @dpcgofficial.bsky.social #PancreaticCancer

Thank you all! Great seeing #PANCPALS group at #PancreasClub 💪🏻💜

@ammaraj.bsky.social

Figure showing most common symptoms and signs of pancreatic cancer at diagnosis. Copyright: Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.

A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs

We are honored to see the #PANCPALS consortium expanding the last few weeks! Already over 80 committed sites globally, and still growing 💪👀

Join us now! Find the joining questionnaire on pancpals.com/joining-ques...

@ammaraj.bsky.social @marcbesselink.bsky.social

Together 💪🏻💜 #PANCPALS #AHPBA2025 @ammaraj.bsky.social @marcbesselink.bsky.social

Come find us at our booth at #AHPBA ! 💜🌞 @ammaraj.bsky.social @marcbesselink.bsky.social

Preperations underway for the #AHPBA Miami 2025 at the PANC-PALS HQ! 🙌🏻📂

Come visit us at our booth! #AHPBA #PANCPALS

@ammaraj.bsky.social

A Vaccine For Pancreatic Cancer Continues To Show Promise In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine had no signs of relapse after three years.

Dr. Vinod Balachandran from @mskcancercenter.bsky.social joins us to discuss the results and what they could mean for cancer treatment.

Come visit our booth at the #AHPBA March 20-23! 🌞

@ammaraj.bsky.social

What are the prognostic factors in patients with resected #PDAC that receive NAT? 💊🏥

#PANCPALS published last week in Annals of Surgery!

Key: prognostic factors for OS differ between chemo-naive and NAT patients.
Find the prognostic tool on our website soon! 💪
@ammaraj.bsky.social

As academic Bluesky grows, researchers find strengths—and shortcomings Platform fosters collegial interactions among scientists, but potentially limits interactions beyond the academic community

🧪 Researchers are leaving X for Bluesky, favoring its chronological feed and low-sensationalism. Philipp Lorenz-Spreen calls it “a good boring.” The algorithm-free platform reduces negative social media effects and boosts smaller accounts but its smaller user base limits outreach. #AcademicSky

#Pancreaticcancer patients who participate in clinical research have better outcomes. 🔬🧪 We're dedicated to helping patients understand their options and find trials that are right for them.

Visit our clinical trials hub at pancan.org/clinicaltrials or contact us today for personalized support. 💜

Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis In this meta-analysis, the most common actionable and undruggable mutations in resected intrahepatic cholangiocarcinoma are determined. Among the heterogen

Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis

academic.oup.com/bjs/article-...

Just another night in the big 🍎

President-elect Trump has picked Dr. Marty Makary, to lead the Federal Drug Administration.
thehill.com/policy/healt...